Serum Adiponectin Levels in Three Different Solid Tumors

Aim: In the recent clinical trials showed that decreased serum adiponectin levels were associated with several cancer types (breast, prostate, endometrium and colorectal cancers; adiponectin have anti-proliferative and proapoptotic effects on cancer cells, in-vitro. In this study, we aimed to investigate, serum adiponectin levels in the pts with three different cancer types (colorectal, lung and gastric cancer) and healthy controls and the association between BMI, tumor stage and serum adiponectin levels. Material and Methods: A total of 25 CRC, 18 lung, 18 gastric cancer pts and sex and age matched 18 healthy controls were enrolled to study. Tumor characteristics (stage, grade, surgery and other treatments), clinical and laboratory findings were recorded. Results: Mean age was 64.310.6 years in the whole patient group (n=61) and 61.810 years in healthy controls. The mean BMI of the case group was lower than that of the control group (24.54.6 kg/m2 and 27.83.3 kg/m2 , p=0.002). Serum adiponectin levels were significantly decreased in the pts (90.323.8 ng/mL vs 114.844.2 ng/mL, p). Serum adiponectin levels were 87.719.2 and 98.531.6 ng/mL in the CRC and gastric cancer pts. Compared to healthy controls, serum adiponectin levels were significantly decreased in the lung and CRC pts (p values 0.021 and 0.020). A significant positive correlation between serum adiponectin and CRP levels in lung cancer pts (Spearman’s rho=0.560, p=0.016). Conclusion: Previous studies showed that serum adiponectin levels were decreased in several cancer types including breast, prostate, endometrium and colorectal cancers. ？n this study, serum adiponectin levels were decreased in cancer pts, significantly decreased in the pts with CRC and lung cancer. Our research emphasizes the importance of adiponectin levels in cancer patients and sheds light on the work to be done in this direction